Katherine Harris, PhDChief Development Officer at Rondo TherapeuticsSpeaker
Dr. Katherine Harris is currently the Chief Development Officer at Rondo Therapeutics. Previously, she was the Vice President of Discovery at Amgen and Teneobio, a multi-specific biotherapeutic antibody company redirecting the immune system to fight cancer. She joined Teneobio when the company started lab operations in 2015, playing a key role in both building and managing a high-throughput antibody discovery platform. Prior to her work at Teneobio, she was a research scientist at Active Motif and SwitchGear Genomics where she focused her efforts on developing a functional genomics platform for small molecule screening. Katherine holds a Ph.D. in Molecular and Cell Biology from the University of California, Berkeley.